Prolacta collects, processes and sells human milk-based products for premature infants
Prolacta Bioscience is a privately held company dedicated to advancing the science of human ilk. The company provides human milk-based neonatal nutritional products for critically ill, premature infants in the neonatal intensive care unit (“NICU”) setting. The company’s lead product, Prolact+, is the first commercially available human milk-derived fortifier and has been shown to improve clinical outcomes for premature infants and drive cost savings to the hospital. Prolacta also markets a number of other human milk-derived products in addition to developing a portfolio of innovative human milk-based products in its pipeline. The company is focused on the quality and safety of nutritional products made from donor breast milk, and operates a pharmaceutical-grade manufacturing facility for the processing of human milk.